Health ❯ Healthcare ❯ Clinical Trials ❯ Patient Outcomes

Risk Stratification

AI Pathomics Tool Beats PD-L1 at Predicting Lung Cancer Immunotherapy Benefit

The biology-guided system uses routine pathology slides to give clearer guidance than PD-L1 on who benefits from immunotherapy.

Immune Atlas Sharpens Myeloma Risk Prediction as Dual-Target CAR T Counters BCMA Loss